University of Chicago, Chicago, IL.
Johns Hopkins University School of Medicine, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.
Am Soc Clin Oncol Educ Book. 2023 Jun;43:e390026. doi: 10.1200/EDBK_390026.
Myeloid malignancies are a manifestation of clonal expansion of hematopoietic cells driven by somatic genetic alterations that may arise in a potential background of deleterious germline variants. As next-generation sequencing technology has become more accessible, real-world experience has allowed integration of molecular genomic data with morphology, immunophenotype, and conventional cytogenetics to refine our understanding of myeloid malignancies. This has prompted revisions in the classification and the prognostication schema of myeloid malignancies and germline predisposition to hematologic malignancies. This review provides an overview of significant changes in the recently published classifications of AML and myelodysplastic syndrome, emerging prognostic scoring, and the role of germline deleterious variants in predisposing to MDS and AML.
髓系恶性肿瘤是由体细胞基因突变驱动的造血细胞克隆性扩张的表现,这些基因突变可能发生在有害种系变异的潜在背景下。随着下一代测序技术变得更加普及,实际经验使分子基因组数据与形态学、免疫表型和常规细胞遗传学相结合,从而加深了我们对髓系恶性肿瘤的理解。这促使对髓系恶性肿瘤的分类和预后预测方案以及对血液恶性肿瘤的种系易感性进行了修订。本文综述了最近发表的 AML 和骨髓增生异常综合征分类中的重大变化、新兴的预后评分以及种系有害变异在 MDS 和 AML 易感性中的作用。